Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2013 – December 31, 2013 Compiled by Uzma Nazim, M.D.

Slides:

Advertisements

Similar presentations

Mammary ductal carcinoma

Advertisements

Baptist Health System General Surgery Residency Program

Pimp Session: Breast By James Lee, MD.

Advances and Emerging Therapy for Lung Cancer

Breast Cancer. Introduction Most common female cancer Accounts for 32% of all female cancer 211,300 new cases yearly and rising 40,000 deaths yearly.

Kevin S. Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Associate Professor of Surgery Harvard.

Breast Cancer in Pregnancy

Role of Nodal Irradiation in Breast Cancer

An update for Illinois Nurses Elizabeth A. Peralta, MD The Breast Center at SIU Springfield, IL May 2011.

Julie R. Gralow, M.D. Director, Breast Medical Oncology, Seattle Cancer Care Alliance Professor, Medical Oncology, University of Washington School of Medicine.

Sentinel Lymph Node Dissection (SND)

What is cancer? A cancer is a malignant tumor, which are cells that multiply out of control, destroying healthy tissues (Dictionary)

Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery

AJCC TNM Staging 7th Edition Breast Case #3

Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.

BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.

Radiotherapy in Carcinoma of the Breast Patrick S Swift, MD Director, Radiation Oncology Alta Bates Comprehensive Cancer Center Berkeley, CA.

Ductal Carcinoma in situ

Neoadjuvant Chemotherapy for Ca Breast CY Choi UCH.

Elshami M.Elamin, MD Medical Oncologist Central Care Cancer Center Wichita, KS, USA

Breast conservation in Locally advanced breast cancer Department of Endocrine Surgery College of Medicine Amrita Institute of Medical Sciences Kochi, Kerala.

Surgery Journal Club By : Ahmad Zahmatkesh Mohammadreza Nazemian.

Nurse Navigators and the Cancer Institute Yousuf A. Gaffar, MD Hematology / Medical Oncology The Cancer Institute University of Maryland St. Joseph Medical.

Breast Cancer Clinical Cases Daniel A. Nikcevich, MD, PhD SMDC Cancer Center April 20, 2009.

Driving the Transition to Individualized Cancer Treatment by Addressing Critical Questions 1 Do I need surgery? chemotherapy? radiation? INVASIVE BREAST.

Ductal Carcinoma In Situ (DCIS)

Suggested guidelines for appropriate patient selection for patients undergoing Accelerated Partial Breast Irradiation at DMC. Tonya Echols Cole, MD.

 Determining the Nature of a Breast Abnormality  It is a procedure that may be used to determine whether a lump is a cyst (sac containing fluid) or a.

Breast Cancer Methods for Early Detection. Breast Cancer What It Is Methods of Early Detection Risk Factors.

A Phase II Study to Evaluate the Safety and Toxicity of Sparing Radiation to the Pathologic N0 Side of the Neck in Squamous Cell.

NYU Medical Grand Rounds Clinical Vignette Daniel P. Eiras, MD, MPH PGY2 December 1, 2010 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.

Breast Cancer: The Profile Ma. Belen E. Tamayo,M.D. Medical Oncologist Makati Medical Center The Medical City.

2014 Cancer Program Performance Outcomes. Introduction Saint Agnes Medical Center has proudly maintained a American College of Surgeons’ Commission on.

Genomic Health, Inc. Yuko Soneoka, Ph.D., J.D. Senior Corporate Counsel, IP Director of Intellectual Property January 31, 2013.

How are Auckland Surgeons Managing the Axilla? E Whineray Kelly, O Pellet, L Neave, J Harman, R Harman. Auckland Breast Cancer Study Group.

Radical Mastectomy is no longer the standard Improved adjuvant and neoadjuvant therapy Chemotherapy Endocrine therapy Radiation treatment Reconstruction.

DL Wickerham MD Deputy Chairman NRG Oncology Oct 5, 2015

MBCG Project Primary Results MEDICALSURVEYS-17 RESEARCH GROUP IN COLLABORATION WITH THE EASO.

Recent and evolving trends in breast and colon cancer by Jeff Kolbasnik.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2014 – December 31, 2014 Compiled by L.Day, RN BSN CCM CCRP OCN 1.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2009 – December 31, 2009.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2011 – December 31, 2011 Compiled by Lynn Day, RN BSN CCM CCRP.

2015 Cancer Program Performance Outcomes. Introduction Saint Agnes Medical Center has proudly maintained a American College of Surgeons’ Commission on.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2012 – December 31, 2012 Compiled by Uzma Nazim, M.D.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2010 – December 31, 2010 Compiled by Lynn Day, RN BSN CCM CCRP.

Basis and Outcome of Axillary Dissection for Node Negative Axilla Gurpreet Singh Dept. Of Surgery P.G.I.M.E.R. These Power Point presentations are free.

SLNB Scenario Group Discussion Presented at: The Sentinel Lymph Node Biopsy Surgery Refresher Course October 29, 2010.

Florida Cancer Plan Phil Roland, MD FACS FACOG Florida State Chair A Commission on Cancer.

Annals of Oncology 24: 2206–2223, 2013 R3 조영학

Quality & Sustainability in Cancer Control: A System Performance Spotlight Report To use a hyperlink, right click on it and select ‘Open Hyperlink’, or.

BREAST BRACHYTHERAPY OUTCOMES EVALUATION Margaret Pierce DNP, APRN, BC University of Tennessee Knoxville, Tennessee.

Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.

Presented at the NAACCR Annual Conference Quebec City June 22, 2010.

ABSTRACT Purpose This retrospective review was conducted to determine if delay in the start of radiotherapy after conservative breast surgery had any detrimental.

PHASE II TRIAL OF HYPOFRACTIONATED BREAST IRRADIATION WITH VMAT-SIB TECHNIQUE: TOXICITY AND EARLY CLINICAL ASSESSMENT IN 270 PATIENTS F. De Rose¹, F. Alongi¹,

Figure 1: a 32-year-old woman presented with RT breast mass, MRI showed false positive diagnosis of cancer. Dynamic contrast enhanced MRI, axial subtraction.

MULTI-DISCIPLINARY CANCER MANAGEMENT John B. Hamner, MD, FACS Assistant Professor Surgical Oncology Tulane University.

Breast Cancer Treatment. Treatment 2 aspects 1. Treatment of the breast itself: “Local Treatment” 2. Treatment of the whole body = “Systemic treatment”

Nicolas Ajkay, MD, FACS Assistant Professor of Surgery

Indications for Breast MR Imaging

Ari Brooks, MD Cancer Surgeon, Big Data End User

Dr Amit Gupta Associate Professor Dept Of Surgery

Surgical Management of the Breast in Breast Cancer

Erica V. Bloomquist, MD Heather Wright, MD

Pathway for patients with suspected Breast Cancer

Treatment Overview: The Multidisciplinary Team

Early and locally advanced breast cancer

Pathway for patients with suspected Breast Cancer

Dr. Damjanovich László Dr. Fülöp Balázs

Presentation transcript:

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2013 – December 31, 2013 Compiled by Uzma Nazim, M.D.

Stage Distribution Total Number of Patients =74 Time Frame Stage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun 12/37 (32.43%) 12/37 (32.43%) 4/37 (10.81%) 3/37 (8.10%) 5/37 (13.5%) 1/37 (2.7%) 37/37 (100%) Jul - Dec 10/37 (27.02%) 12/37 (32.43%) 9/37 (24.3%) 4/37 (10.8%) 2/37 (5.40%) 0/37 (0%) 37/37 (100%) Jan-Dec 22/74 (29.7%) 24/74 (32.43%) 13/74 (17.5%) 7/74 (9.4%) 7/74 (9.4%) 1/74 (1.3%) 74/74 (100%) Compiled by Uzma Nazim, M.D.

Time FrameStage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun Preoperative Core 12/12 (100%) 15/15 (100%) 4/4 (100%) 2/3 (66.7%) 2/2 (100%) 1/1 (100%) 36/37 (97.3%) Jul – Dec Preoperative Core 9/10 (90%) 13/13 (100%) 9/9 (100%) 4/4 (100%) 1/1 (100%) 0/0 (0%) 36/37 (97.3%) Jan-Dec Preoperative Core 21/22 (95.5%) 28/28 (100%) 13/13 (100%) 6/7 (85.7%) 3/3 (100%) 1/1 (100%) 72/74 (97.3%) Mode of Diagnosis Total Number of Patients = % of patients had diagnosis established on preoperative core needle biopsy Exceptions2/74 Pts. established diagnosis on excisional biopsy as the primary site is not amenable to image guided biopsy Compiled by Uzma Nazim, M.D.

Tumor Board Discussion Total Number of Patients =74 Time Frame Stage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun Discussed 11/12 (91.6%) 11/12 (91.66%) 4/4 (100%) 3/3 (100%) 5/5 (100%) 0/1 (0%) 34/37 (91.9%) Jul – Dec Discussed 9/10 (90%) 12/12 (100%) 9/9 (100%) 4/4 (100%) 2/2 (100%) 0 (0%) 36/37 (97.3%) Jan-Dec Discussed 20/22 (90.9%) 23/24 (95.8%) 13/13 (100%) 7/7 (100%) 7/7 (100%) 0/1 (0%) 70/74 (94.5%) 94.5% of patients were discussed in the multidisciplinary tumor conference Compiled by Uzma Nazim, M.D.

Time Frame Stage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun MDC seen 8/12 (66.6%) 14/15 (93.3%) 4/4 (100%) 3/3 (100%) 0/2 (0%) 0/1 (0%) 29/37 (78.3%) Jul – Dec MDC seen 8/10 (80%) 7/13 (53.8 %) 7/9 (77.7%) 3/4 (75%) 0/1 (0%) 0/0 (00%) 25/37 (67.57%) Jan-Dec MDC seen 16/22 (72.7%) 21/28 (75%) 11/13 (84.6%) 6/7 (85.7%) 0/3 (0%) 0/1 (0%) 54/74 (72.97%) Multidisciplinary Assessment (Surgical, Medical and Radiation Oncologist) Total Number of Patients = 74 Exceptions: 20/74 Mastectomy 6/20 Patients with DCIS 6/20 Patient deceased 2/20 Patient transferred 2/20 Patients with advanced metastatic disease 4/20 Compiled by Uzma Nazim, M.D.

Time FrameStage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun Assigned 12/12 (100%) 15/15 (100%) 4/4 (100%) 3/3 (100%) 2/2 (100%) 0/1 (0%) 36/37 (97.3%) Jul – Dec Assigned 10/10 (100%) 13/13 (100%) 9/9 (100%) 4/4 (100%) 1/1 (100%) 0 (0%) 37/37 (100%) Jan-Dec Assigned 22/22 (100%) 28/28 (100%) 13/13 (100%) 7/7 (100%) 3/3 (100%) 0/1 (0%) 73/74 (98.65%) Nurse Navigation Total Number of Patients = 74 Exceptions 1/74 (1.35%) Patient sought treatment in Mexico Compiled by Uzma Nazim, M.D.

Time FrameStage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun Yes 0/12 (0%) 15/15 (100%) 4/4 (100%) 3/3 (100%) 0/2 (0%) 0/1 (0%) 22/37 (59.4%) Jul – Dec Yes 1/10 (10%) 11/13 (84.6%) 8/9 (88.9%) 3/4 (75%) 0/1 (0%) 0 (0%) 23/37 (62.16%) Jan-Dec Yes 1/22 (4.5%) 26/28 (92.8%) 12/13 (92.3%) 6/7 (85.7%) 0/3 (0%) 0/1 (0%) 45/74 (60.8%) CAP Compliance Total Number of Patients = 74 Compiled by Uzma Nazim, M.D. Exceptions 29/74(39%) Margins can not be assessed 9/29 Patient transferred 3/29 Patient deceased during treatment 3/29 Mastectomy 5/29 Surgery not done 3/29 DCIS 6/29

Axillary Staging Total Number of Patients = 74 Total Number of Patients with Invasive Cancer = 52 Number node positive patients on needle biopsy9/52(17.30%) Number of pts. with Stage IV disease 3/52(5.76%) Number of patients eligible for SLNB40/74(54.05%) Number of patients with SLNB31/40(77.5%) Exceptions9/40(22.5%) Determined low risk (unlikely to change treatment plan) 7/9(77.7%) Patient transferred 2/9(22.22%) Compiled by Uzma Nazim, M.D.

Axillary Dissection Total Number of Patients = 74 Total Number of Patients with Invasive Cancer =52 Number of patients with stage IV3/52(5.76%) Number of patients with node positive disease 18/52(34.61%) Number of patients eligible for ALND18 Number of patients with ALND7/18(38.9%) Exceptions11/18(61.11%) Low risk for non-SLN mets. on MSKCC nomogram 7/11(63.6%) Patient deceased before final surgery1/11(9%) Surgery done at some other facility 1/11(9%) Final surgery not done yet2/11(18.18%) Compiled by Uzma Nazim, M.D.

Time Frame Stage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun Yes 9/12 (75%) 15/15 (100%) 4/4 (100%) 1/3 (33.3%) 0/2 (0%) 0/1 (0%) 29/37 (78.4%) Jul – Dec Yes 8/10 (80%) 6/13 (46.1%) 6/9 (66.6%) 2/4 (50%) 0/1 (0%) 0 (0%) 22/37 (59.5%) Jan-Dec Yes 17/22 (77.27%) 21/28 (75%) 10/13 (76.9%) 3/7 (42.8%) 0/3 (0%) 0/1 (0%) 51/74 (69%) Breast Conservation Total Number of Patients = 74 Number of early stage pts. (0, I and II) with breast conservation 48/63(76.1%) Mastectomies done 18/74(24.3%) Compiled by Uzma Nazim, M.D.

Post-lumpectomy Radiation Total Number of Patients =74 Number of patients with lumpectomy 51/74 (68.9%) Number of patients eligible for Radiation 51 Number of patients radiated 43/51(86.2%) Number of patients radiated within 12 months 43/43(100%) Exceptions 8/51(15.7%) Patient had mastectomy after initial lumpectomy 2/8(25%) Patient with small DCIS in prior radiation field 1/8(12.5%) Patient deceased during chemotherapy 1/8(12.5%) Patient refused to get radiation 4/8(50%) Compiled by Uzma Nazim, M.D.

Post-Mastectomy Radiation Total Number of Patients = 74 Number of patients with mastectomy 18/74 (24.3%) Number eligible for radiation (>T3 or >N2) 5/18(27.7%) Number of patients radiated 2/5(40%) Number of patients radiated within 12 months 2/2 (100%) Exceptions 3/5(60%) Patient refused radiation 1 /3(33.3%) Patient got treatment from other facility 1/3( 33.3%) Patient deceased during chemotherapy 1/3(33.3%) Compiled by Uzma Nazim, M.D.

Systemic Chemotherapy - I Total Number of Patients = 74 ER negative patients with cancer12/74 (16.2%) ER negative patients with DCIS 2/12(16.66%) Number eligible for chemotherapy(exclude DCIS)10/12(83.3%) Number treated with chemotherapy 10/10 (100%) Exceptions 0 Number with chemotherapy within 4 months 10/10(100%) Compiled by Uzma Nazim, M.D.

Systemic Chemotherapy - II Total Number of Patients = 74 ER positive patients with cancer62/74 (83.73%) Number treated with chemotherapy21/62(33.98%) Number with chemotherapy within 4 months21/21 (100%) Exceptions 0(0%) Compiled by Uzma Nazim, M.D.

Systemic Endocrine Therapy Total Number of Patients = 74 Number of ER positive patients 62/74 (83.78%) Number treated with endocrine therapy 48/62 (77.4%) Exceptions 14/62(22.5%) Determined risk > benefit 3/14 (21.4%) Patients with co morbidities 3/14 (21.4%) Patient non compliant 2/14(14.2%) Patient transferred 3/14(21.4%) Patient deceased 3/14(21.4%) Number with endocrine therapy within 1 year 48/48 (100%) Compiled by Uzma Nazim, M.D.

Rehabilitation Total Number of Patients =74 Number enrolled in CPRP (PT/OT)44/74 (59.5%) Exceptions30/74 (40.5%) Services were available but structured program is pending definitive establishment, whereby every patient gets a baseline arm girth and shoulder range of motion documented; prospective data is maintained with a pre-designed schedule. Pts. enrolled in CPRP in /107 (22.43%) Pts. enrolled in CPRP in /74 (49%) Pts. enrolled in CPRP in /74(59.5%) Improvement over % Compiled by Uzma Nazim, M.D.

Genetic Counseling Total Number of Patients = 74 Number of patients with family history or < 45 years49/74 (66.2%) Number received genetic counseling20/49(41%) Number tested13/20(65%) Positive 4/13(30%) Negative9/13(70%) Number refused testing 3/20(15%) Patient transferred to Mexico 1/20(5%) No documentation in the chart 3/20(15%) Exceptions 29/49(59%) Compiled by Uzma Nazim, M.D.

Reconstruction For Mastectomy Total Number of Patients = 74 Number of patients with mastectomy18/74 (24.32%) Number of patients with reconstruction12/18(66.66%) Exceptions 6/18(33.3%) Pts. Offered but refused 5/6(83.33%) Stage IV patient with palliative mastectomy 1/6(16.66%) Number of patients with reconstruction in 20129/20(45%) Improvement over % Compiled by Uzma Nazim, M.D.

Time Frame Trial / StudyEligible N (%) Participation N (%) Jan – Jun B-SMART44(100%) CCIP21(50%) SPOC66(100%) MULTIPLE STUDIES2222(100%) Total 34/37(91.9%)33/34(97%) Jul - Dec B-SMART73(43%) CCIP00(0%) SPOC1110(91%) MULTIPLE STUDIES1613(81.2%) Total 34/37(91.9%) 26/34(76.4%) GRAND TOTAL68/74(92%)59/68(87%) Trial Participation Total Number of Patients = 74 Patients participated in trials for /71(75%)